uniQure
QURE
Market cap $828M

16.98 USD

+1.51

9.76%

At close Dec 20, 4:00 PM EST

After hours

16.85

-0.13

0.77%

1 day

9.76%

5 days

8.71%

1 month

197.89%

3 months

216.79%

6 months

272.37%

Year to date

145.02%

1 year

172.12%

5 years

-75.52%

10 years

11.42%

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 480

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,809 funds

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

78% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 18

51% more call options, than puts

Call options by funds: $4.99M | Put options by funds: $3.31M

22% more capital invested

Capital invested by funds: $159M [Q2] → $193M (+$34.2M) [Q3]

12% more funds holding

Funds holding: 116 [Q2] → 130 (+14) [Q3]

6.97% more ownership

Funds ownership: 73.11% [Q2] → 80.08% (+6.97%) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 40

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

18%

upside

Avg. target

$34

99%

upside

High target

$58

242%

upside

8 analyst ratings

6 positive

75%

2 neutral

25%

0 negative

Mizuho Uy Ear 50% 1-year accuracy 6 / 12 met price target	18%upside $20	Neutral Maintained	19 Dec 2024
Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target	88%upside $32	Buy Maintained	16 Dec 2024
Goldman Sachs Salveen Richter 29% 1-year accuracy 5 / 17 met price target	18%upside $20	Neutral Maintained	12 Dec 2024
Leerink Partners	159%upside $44	Outperform Maintained	11 Dec 2024
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target	18%upside $20	Outperform Maintained	11 Dec 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about QURE published over the past 30 days

Positive

The Motley Fool

1 week ago

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.

Positive

Zacks Investment Research

1 week ago

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

Positive

Investors Business Daily

1 week ago

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment. The post UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug appeared first on Investor's Business Daily.

Neutral

GlobeNewsWire

1 week ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~

Positive

Zacks Investment Research

3 weeks ago

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet

The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Positive

Zacks Investment Research

3 weeks ago

What Makes uniQure (QURE) a New Buy Stock

uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral

GlobeNewsWire

1 month ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE).

$uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy$